Northwestern Faculty, Post-docs and Students
 
Please join INVO and Lakeside Discovery for this May seminar which aims to provide insight into antibody therapeutic discovery and development in the academic setting. Experts will examine the state-of-the-art science in the field and provide details on resources available at Northwestern to accelerate antibody discovery.

Over the past 5 years, recombinant antibodies have been established at a growing rate into clinical practice for the treatment of diseases ranging from cancer to autoimmune and infectious diseases. The seminar will cover various aspects related to the commercialization of therapeutic antibodies, with the hope of fostering PI interest in future submissions to Lakeside Discovery, a drug discovery collaboration between Northwestern University and Deerfield Management.

The next Lakeside Discovery Request for Proposal (RFP) cycle opens on August 15, 2019.

This seminar is sponsored by INVO, Lakeside Discovery and Deerfield Management.

EVENT AGENDA
Prentice Women's Hospital, 3rd Floor, L North Conference Room

OUR SPEAKERS

Karen Heidelberger, M.B.A.
Chief Partnership and Communications Officer
Partner, Deerfield Management

Ms. Heidelberger is a Partner and the Chief Partnership and Communications Officer at Deerfield, where she is responsible for relationships with investors, partner companies, and institutions, and other interested parties. Prior to this role, Ms. Heidelberger was a Trader at Deerfield for over a decade.  In this capacity, she was responsible for trading in public securities on behalf of the Funds and developing and communicating market information to the Firm. Prior to joining Deerfield in 2002, Ms. Heidelberger was a Vice President in the Sales and Trading division of Merrill Lynch.  Also at Merrill, she served as a Conflicts Coordinator in the Mergers and Acquisitions department. In this role she was responsible for ensuring that Merrill Lynch was clear of legal and business conflicts of interest before the firm was able to accept an assignment. Ms. Heidelberger has served on the board of the Cornell Institute for Healthy Futures since 2016.  She graduated from the Cornell University, School of Hotel Administration and earned her M.B.A. from Harvard Business School.

William Slattery
Partner, Deerfield Management
Joint Steering Committee Member, Lakeside Discovery

Mr. Slattery is a Partner on the Biotherapeutics group at Deerfield, which he joined in 2000. He began his professional career studying immune system complications associated with End Stage Renal Disease. Prior to joining Deerfield, Mr. Slattery was a senior healthcare analyst between 1990 and 2000 at Amerindo Investment Advisors overseeing biotechnology investments. He has held various positions in research including those at National Medical Enterprises, Johnson & Johnson, and HMSS. Mr. Slattery is the Chairman of Gilda’s Club New York City, a non-profit organization supporting cancer patients and their families. Mr. Slattery has a degree in Biology and Chemistry from State University of New York at Albany and completed coursework in Immunology at the Graduate School-New Brunswick, Rutgers University.


Larry Green, Ph.D.
Founder and CEO, Ablexis
Co-inventor, AlivaMab Mouse
CEO, AlivaMab Discovery Services

Larry is CEO and founder of Ablexis, and co-inventor of the AlivaMab Mouse. He also serves as CEO of AlivaMab Discovery Services. Larry has over a quarter century of experience in designing, creating and using transgenic mouse platforms for antibody drug discovery. Larry joined Aliva Biopharmaceuticals, Inc. in 2008 as CEO, where he optimized the blueprint for AlivaMab Mouse and procured a Series A financing, resulting in the founding of Ablexis, LLC in 2009. Prior to joining Aliva, he was a co-inventor of the XenoMouse® technology at Cell Genesys and was a scientific founder of the spin-out of Abgenix, where he served as designer and team leader for making improved versions of the XenoMouse® technology, director of antibody discovery operations, leader of the collaborations group, and the senior research representative on joint steering committees in alliances with Amgen, AstraZeneca, Pfizer amongst other companies.

Larry is an inventor on several dozen patents covering immunoglobulin transgenic mice and therapeutic antibodies. He received his Ph.D. in Molecular and Cellular Biology from the University of Wisconsin-Madison and did postdoctoral research at the University of Colorado at Boulder and Stanford University.


Amie Phinney, Ph.D., M.B.A.
Director of Alliance Management, Lakeside Discovery

Amie joined Lakeside Discovery in August 2018. Amie brings extensive experience in drug discovery, preclinical development and alliance management. Amie began her pharmaceutical career as a Senior Scientist, Preclinical Project Director and Program Manager in the Neuroscience Division of Solvay Pharmaceutical in the Netherlands. Later at Abbott Labs and AbbVie Pharmaceuticals, Amie continued to develop her expertise in the development of drug candidates, specializing in partnered discovery projects. In her roles as a Collaboration Project Manager, Operations Director and Alliance Leader, Amie successfully led multi-party, cross-functional project teams through all stages of drug discovery. Before joining industry, Amie was a research fellow at the University of Toronto and the Free University of Amsterdam. She holds a PhD in Biomedical Research from the University of Basel in Switzerland and an MBA from Lake Forest Graduate School of Management in Illinois.